Through both direct and indirect actions on multiple aspects of the detrimental transformation of EAT, GLP-1 and dual GLP-1/GIP receptor agonists offer a novel approach to obesity treatment that may influence metabolic pathways leading to obesity-related cardiomyopathy. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.